The Epidermal Growth Factor Receptor in Breast Cancer

被引：53

作者：

Fox, Stephen B. ^{[1
]}

Harris, Adrian L. ^{[1
]}

机构：

[1] Univ Oxford, John Radcliffe Hosp, ICRF Mol Oncol Lab, Dept Cellular Sci, Oxford OX3 9DU, England

来源：

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA | 1997年 / 2卷 / 02期

关键词：

Prognostic phenotype; embryogenesis; adipose tissue; sialoadenectomy;

D O I：

10.1023/A:1026399613946

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The epidermal growth factor receptor (EGFR)(3) is a 170 kD transmembrane tyrosine kinase activated by several ligands. It is required for normal mammary development and lactation and is aberrantly expressed in approximately 40% of breast carcinomas, particularly those with a poor prognostic phenotype. Since EGF receptor levels are elevated in a high proportion of many tumor types its potential as a therapy target is being investigated using the EGF receptor to target toxins, as well as drugs that interfere with signaling and anti-receptor antibodies. These approaches are likely to be most effective when used in the adjuvant situation in combination with chemotherapy.

引用

页码：131 / 141

页数：11

共 112 条

[1]

ABE O, 1992, LANCET, V339, P71

[2] EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY [J].